Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Germinal center kinase inhibition enhances iberdomide’s anti-myeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism in both in vitro and in vivo models.”
Title: GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism
Authors: Shirong Li, Josefine Krüger, Guifen Liu, Huihui Ma, Michael S. Hughes, Rajshekhar Chakraborty, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch, Jing Fu
You can read the Full Article on Blood Neoplasia.
You can find more posts featuring Robert Orlowski on OncoDaily.
